Citi raised the firm’s price target on Amgen (AMGN) to $305 from $300 and keeps a Neutral rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Promising Study on Advanced Gastric Cancer: What Investors Need to Know
- Amgen price target raised to $326 from $315 at UBS
- Amgen’s Phase 3 Study on Etelcalcetide: A Potential Game-Changer for Pediatric Kidney Disease
- Amgen’s Phase 2 Asthma Study: A Potential Game-Changer for Rocatinlimab
- Amgen’s Promising Phase 3 Study: Maridebart Cafraglutide for Obesity in Type 2 Diabetes